A modified random oligonucleotide-based combination therapy for adjuvant treatment of pancreatic ductal adenocarcinoma

  • Authors:
    • Juergen Tepel
    • Christina March
    • Thomas Ketterer
    • Matthias Kapischke
    • Alexander Arlt
    • Bernd Kremer
    • Holger Kalthoff
    • Marie-Luise Kruse
  • View Affiliations

  • Published online on: May 1, 2006     https://doi.org/10.3892/ijo.28.5.1105
  • Pages: 1105-1112
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anti-cancer therapy in pancreatic ductal adenocarcinoma (PDAC) is mostly based on surgical removal or palliative therapy using antimetabolites, like 5'-fluorouracil or gemcitabine. Adjuvant treatment using these chemotherapeutics has recently proven a beneficial concept, though general survival rates are still poor. Most recently, combination therapy of gemcitabine with other targeted drugs was evaluated in clinical trials. We present here a study performed in a mouse orthotopic xenotransplant model of PDAC, using an oligo-nucleotide-based approach. We have shown previously that antisense oligonucleotides against p53 reduce the weight of orthotopic pancreatic tumours in immune-deficient mice. We further characterised terminal modifications of phosphorothioate oligonucleotides in vitro and found a random, unrelated control sequence carrying a D,L-α-tocopherol modification at the 5' and 3' ends to be most efficient in induction of cell death in PancTu-1 cells. Modified random oligonucleotide (MRON) were thus further tested in vivo. MRON showed a reduction of tumour weight in established primary orthotopic tumours in SCID/bg mice. In a surgically adapted pre-clinical model, where primary tumours were resected and animals received adjuvant treatment, MRON was very efficient in suppression of relapse and metastasis, when combined with gemcitabine. While the exact molecular mechanism of MRON activity still needs to be elucidated, the compound showed a remarkable preference for uptake into tumour cells in vivo.

Related Articles

Journal Cover

May 2006
Volume 28 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tepel, J., March, C., Ketterer, T., Kapischke, M., Arlt, A., Kremer, B. ... Kruse, M. (2006). A modified random oligonucleotide-based combination therapy for adjuvant treatment of pancreatic ductal adenocarcinoma. International Journal of Oncology, 28, 1105-1112. https://doi.org/10.3892/ijo.28.5.1105
MLA
Tepel, J., March, C., Ketterer, T., Kapischke, M., Arlt, A., Kremer, B., Kalthoff, H., Kruse, M."A modified random oligonucleotide-based combination therapy for adjuvant treatment of pancreatic ductal adenocarcinoma". International Journal of Oncology 28.5 (2006): 1105-1112.
Chicago
Tepel, J., March, C., Ketterer, T., Kapischke, M., Arlt, A., Kremer, B., Kalthoff, H., Kruse, M."A modified random oligonucleotide-based combination therapy for adjuvant treatment of pancreatic ductal adenocarcinoma". International Journal of Oncology 28, no. 5 (2006): 1105-1112. https://doi.org/10.3892/ijo.28.5.1105